VCYT: Cup Handle detected on 1 Jun 2026

VCYT is forming a cup-and-handle pattern with a structure score of 15.0 and breakout score of 13.0, indicating textbook price structure. The stock is trading at $46.34, having moved sharply higher over the past month (+45.81%), and sits just 8.62% below its 52-week high. Key support is anchored at $37.66, with initial resistance at $41.19. Volume is neutral at 1.04x average; the pattern's 84.0 overall score reflects solid technical setup. RSI at 69.1 signals near-overbought conditions. The measured move target is $50.19, implying approximately 8% upside from current price.

Veracyte reported exceptionally strong Q1 2026 results on May 5, 2026, with revenue growing 21% to $139.1 million and testing revenue up 26% to $135.1 million. Decipher revenue surged 30% to $86.5 million while Afirma grew 21% to $46.4 million, with net income reaching $28.7 million. Management raised full-year 2026 guidance citing profitability targets exceeded and significant upcoming product launches. Notably, the company is hosting an investor call today (June 1, 2026) to discuss phase III clinical trial data from OPTIMA and ENZAMET trials for Prosigna Breast and Decipher Prostate tests being presented at ASCO. Management also announced upcoming launches of Prosigna LDT and TrueMRD in Breast, Bladder, Prostate and Thyroid cancers. This combination of accelerating fundamentals, positive clinical evidence, and product catalysts provides tailwind for the technical pattern.

A successful breakout above $41.19 resistance would target the conservative measure of $50.19, representing 8.4% upside. Historical cup-and-handle patterns show approximately 54.49% win probability (per pattern scoring), suggesting better-than-coin-flip odds. Volume confirmation is marginal—current relative volume of 1.04x is adequate but unspectacular, so sustained conviction above resistance is essential for the breakout to hold. The pattern fails definitively below $37.66 support; closure below this level invalidates the setup and signals reversal to the downside.

Several headwinds merit caution. RSI at 69.1 is approaching overbought territory (>70), suggesting limited room for extension before pullback. Stock has already gained 45.81% in the prior month and is only 8.62% from 52-week highs, leaving minimal cushion for momentum reversal. Beta of 1.26 means VCYT is 26% more volatile than the broad market, amplifying downside risk during sector or macro selloffs. The announced investor call scheduled for today (June 1) to discuss ASCO trial data presents event risk—negative data surprises could trigger sharp selling. Additionally, the stock's substantial run-up raises bar for continued upside and increases probability of profit-taking before new catalysts arrive.